PROF - צמיחת הכנסות ב-12 חודשים נגררים Profound Medical Corp.

Profound Medical Corp. is implementing the TULSA-PRO system, replacing traditional prostate surgery with non-invasive ablation. Demand for the equipment remains stable, while quarterly seasonality is mitigated by the critical importance of the therapy for oncology centers. The proprietary precision of these methods allows the company to confidently expand its share in urology. The company's TTM annual revenue growth rate demonstrates business resilience, with the latest value recorded as 65.90.

Assessing the financial stability of Profound Medical Corp. (PROF) requires an analysis of the actual demand for the TULSA-PRO system for non-invasive prostate cancer treatment. The LTM sales growth rate mathematically strips revenue of seasonality and market noise, allowing investors to distinguish the fundamental expansion of the partner clinic network from random price fluctuations and avoid purchasing an overvalued asset.